Neurology News

The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

DENVER – Individuals who had migraine with aura were more likely to have atrial fibrillation compared with those who had a migraine without aura, a presenter said at the American Headache Society annual meeting.

During his presidential address at the AMA House of Delegates meeting, Gerald E. Harmon, MD, outlined five actions that he said policymakers must take to better support physicians.

Climate change is a public health crisis threatening the well-being of all people, the AMA declared via a policy it adopted during the annual meeting of its House of Delegates.

An analysis of data registries from three countries showed the AstraZeneca vaccine was associated with small but increased rates of hospital contacts for thromboembolic coagulation disorders, especially for thrombocytopenia.

CHARLOTTE, N.C. — Cognitive behavioral therapy for insomnia is a “feasible and acceptable” treatment for people regularly using cannabis to help with sleep, J. Todd Arnedt, PhD, said at the SLEEP 2022 meeting.

DENVER — Treatment with Vyepti was associated with a sustained reduction in the frequency of episodic and chronic migraines over 6 months, researchers reported at the American Headache Society annual scientific meeting.

DENVER — Trudhesa nasal spray provided pain relief for up to three consecutive migraine attacks in an open-label, 52-week phase 3 trial, researchers said at the American Headache Society annual scientific meeting.

DENVER — Psychedelic use, specifically psilocybin, is effective in treating cluster headaches and migraines, Emmanuelle Schindler, MD, PhD, said at the American Headache Society annual scientific meeting.

DENVER — Monoclonal antibodies have shown promise as an emerging treatment for migraine, Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, said at the American Headache Society annual scientific meeting.